SAMRC

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Retrieved on: 
Friday, April 19, 2024
Education, Science, Mentorship, MenAfriVac, Death, Vaccine, Life, Government, Rising Star Award, Klugman, Basta, Global health, Vaccination, Public, Diarrhea, Neonatal sepsis, Princeton University, Developing country, SAMRC, Meningococcal vaccine, Gold medal, DRS, Child, McGill University, RSV, Tomer Capone, Infection, National academy, Pneumonia, Pregnancy, Publication, Health, Research, Meningococcal disease, Sabin Vaccine Institute, Gold, Rotavirus, Student, Organization, GBS, University of the Witwatersrand, University, Canada Research Chair, Florida Department, CBE, Policy, Fever Dream, Disease, Meningitis, HPV, COVID-19

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

Key Points: 
  • Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute.
  • He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist.
  • His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines.
  • Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Retrieved on: 
Wednesday, November 1, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Grand duchy, Food, Face, VWS, Disease, Gonorrhea, MHLW, Partnership, The Lancet, National Rural Development Partnership, Infection, Nursing care plan, Reproduction, SAMRC, Azithromycin, Hope, Physician, Prevalence, HIV, Ceftriaxone, BMBF, Neisseria gonorrhoeae, University, Therapy, Patient, Food and Drug Administration, Infertility, DFID, Heart, BMG, NIAID, MD, DHSC, AMR, BZ, Clinical trial, World Health Organization, Zoliflodacin, Woman, Multidrug-resistant bacteria, FOPH, South African Medical Research Council, Death, Ministry, Pharmaceutical industry, Vaccine, Medicine

These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.

Key Points: 
  • These positive preliminary findings offer hope for patients with this condition, particularly in the face of rising antibiotic resistance to current regimens.
  • It also paves the way for a new research and development model in the global fight against antimicrobial resistance (AMR).
  • Now, the positive results of this landmark Phase 3 trial confirm that zoliflodacin has the potential to tackle the most difficult-to-treat gonorrhea infections.
  • This builds on the critical Phase 2 clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

Audere and South Africa-Based Medical Diagnostech Partner to Bring Africa’s First Home-Grown COVID-19 Antigen Test to Market with Digital Companion App

Retrieved on: 
Friday, March 11, 2022
Research, Technology, Infectious Diseases, Software, Philanthropy, Biotechnology, General Health, Health, Foundation, Science, South African Medical Research Council, ISO, HIV, Disease management, Health Products Regulatory Authority, Pregnancy, Department, Partnership, Research, Public health, Machine learning, Google Play, Accreditation, App Store (iOS/iPadOS), Membrane protein, Investment, Technology Innovation Agency, Bill, SAMRC, Department of Science and Innovation, MD, Artificial intelligence, Capsid, Health equity, SAHPRA, Solution, COVID-19, Innovation, Global health, Bill & Melinda Gates Foundation, Immunity, Severe acute respiratory syndrome coronavirus 2, Infection, Malaria, Medical device, Mobile phone, Pharmaceutical industry, Audere, Medical Diagnostech, AUDERE, MEDICAL DIAGNOSTECH

Access to aggregated test data will provide a comprehensive understanding of disease prevalence, enabling more informed surveillance and disease management.

Key Points: 
  • Access to aggregated test data will provide a comprehensive understanding of disease prevalence, enabling more informed surveillance and disease management.
  • As a South African, I have first-hand experience with the test inequity challenges faced by individuals in my country.
  • I feel extreme pride to partner with Medical Diagnostech and support the roll-out of a COVID-19 rapid test made on the continent, for the continent.
  • The increased public health reporting capabilities enabled by digitizing rapid diagnostic test result data are crucial to South Africas evolving public health strategy.

South Africa Tourism Industry Calls on UK to Lift Red List Restrictions Following New Scientific Research

Retrieved on: 
Tuesday, December 14, 2021
Health, Infectious Diseases, Transportation, Vacation, Lodging, Destinations, Travel, Omicron, Global South, Medical Research Council, Government, Travel, Tourism, Life, Holiday, Public health, Association, Anger, Comment, Woman, Income, Human, COVID-19, Discovery Health, Risk, CEO, SAMRC, Pfizer, Knowledge, Infection, Interview, High-dependency unit, Tshifhiwa Munyai, Policy, Mining, Food, Carbon, Pharmaceutical industry

The UK needs to act immediately to remove its discriminatory red list and begin rebuilding trust with the Global South where its travel policy is causing anger and resentment.

Key Points: 
  • The UK needs to act immediately to remove its discriminatory red list and begin rebuilding trust with the Global South where its travel policy is causing anger and resentment.
  • The UK is the largest overseas market for tourism into South Africa.
  • In a typical year approximately 450,000 British passport holders travel into South Africa, contributing to national income from tourism of R265 billion ($18bn).
  • The Tourism Business Council of South Africa (TBCSA) is the umbrella organisation representing the unified voice of business in the travel and tourism sector.